News

Study claims GMO cancer risk
Enlarge image

PolicyEUUKFranceSpain

Study claims GMO cancer risk

21.09.2012 - Researchers from the organisation Criigen have published a GMO feeding study suggesting a cancer risk in mice. Critics say the study design was not appropriate.

In the peer reviewed journal Food and Chemical Toxicology a team headed by Criigen president Gilles-Eric Seralini report that lab mice fed with Monsanto’s GM maize NK603 or with the herbicide Glyphosate developed faster tumours than control mice. While treated female rats died 2-3 fold more frequently than controls, male rats which received the GMO or herbicide diet over 2 years developed tumours, which were up to 4 times larger than in control mice and occurred earlier in their life cycle, accompanied by kidney defects in both sexes.

However, critics questioned the credibility and reliability of the data. "The methods, stats and reporting of results are all well below the standard I would expect in a rigorous study – to be honest I am surprised it was accepted for publication“, stated Prof. Dr. David Spiegelhalter from University of Cambridge, UK, explaining that there was no full data set, no relevant number of animals involved to demonstrate statistical significance and no dose-dependent effect confirming the conclusions of the study authors. Prof. Dr. Maurice Moloney, chief of Rothamsted Research, pointed to the fact that the rat species used by the French researchers is extremely susceptible to developing spontaneous cancers, with up to 86% in wild-type males and 72% in normal females. According to Dr. Wendy Harwood, John Innes Centre, „without access to the full data, we can only say that these results cannot be interpreted as showing that GM technology itself is dangerous.“ Some researchers also criticised that it was not good scientific practice to give the data to the press before making them public to the scientific community. Others such as Prof. Dr. Jose Miquel Mulet from University of Valencia presumed the study was politically motivated: The reports of Criigen are put forward by the French authorities as justification to maintaining bans on cultivating GMOs,“he stressed. French Prime Minister Jean-Marc Ayrault stated in Paris: "The government is keeping its moratorium on the cultivation of GMO seeds currently authorised in the European Union." 

A spokesman of the European Food watchdog EFSA said it will consider the paper’s relevance (http://www.efsa.europa.eu/en/press/news/120919b.htm). The study appears as a direct attack on the EFSA’s methods. However, recently, an independent study carried out by Ernst & Young confirmed the agency’s assessments had excellent scientific quality.  

Since the foundation of Criigen in 2001, its researchers have questioned the design of animal studies used to assess GMO safety. The organisation is financed through contract research . Although its researchers carry out contract studies for Greenpeace and Carrefour, the large French food retailer which claims its products to be GM-free, its researchers say the organisation is independent.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/study-claims-gmo-cancer-risk.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • IMMUPHARMA (UK)26.50 GBP-10.17%
  • DBV TECHNOLOGIES (F)53.40 EUR-5.79%
  • FLAMEL TECHNOLOGIES (F)11.37 USD-4.29%

TOP

  • BIOFRONTERA (D)3.26 EUR39.3%
  • SYNAIRGEN (UK)35.50 GBP36.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)47.10 SEK-22.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1818.9%
  • NICOX (F)8.01 EUR321.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.7%
  • BB BIOTECH (D)44.01 EUR-83.2%
  • CYTOS (CH)0.25 CHF-78.6%

No liability assumed, Date: 05.05.2016